

The 3P Project for a **one month or less** treatment for TB that works for **everyone, everywhere.**



PUSH • PULL • POOL

Better TB treatment. Faster.

Drug resistant TB Treatment


“To hell with TB; I’ve had enough. If you try to make it nice instead of saying it straight, people easily ignore it... It took my hearing away, now it wants to take my life...”



- Phumeza, 22 years old, diagnosed with XDR-TB in June 2010

Global Reach

Countries that had notified at least one case of extensively drug-resistant tuberculosis by the end of 2012



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: *Global Tuberculosis Report 2013*. WHO, 2013.

© WHO 2013. All rights reserved.



The case for action is clear



- Funding levels for R&D need to increase overall
- The current incentive structures do not deliver for TB
- New, well targeted incentives must be put in place to:
 - bring new researchers and developers to the problem
 - re-engage traditional investors
 - ensure a healthy drug development pipeline
 - create an open collaborative framework that enables several drugs to be developed in parallel as ***combination*** regimens

The 3P project

A new way of doing science with the patient at its core.

Rewarding the best science, ensuring collaboration so treatments that work for all are developed quickly.

The '3P project' will deliver **a one month or less cure for TB that works for everyone, everywhere.**


3Ps: Push + Pull + Pool



A mix of incentives & managing and sharing of IP:

- **PUSH** funding to finance R&D activities upfront (i.e. through grants)
- **PULL** funding to incentivise R&D through financial rewards on achieving objectives (i.e. milestone prizes)
- **POOL** of IP and data for open collaborative research and fair licensing for affordable products

R&D Financing Structure



Legend

- Various TB Compounds
- ★ Milestone Prize
- ➔ Grant funding

★
Large Milestone Prize for compounds entering the pool for clinical development (Phase I)

➔ ➔ ➔
Grant funding for regimen trials (phases I – III) from existing and new sources

The 3P Project

The '3P project' will deliver **a one month or less cure for TB that works for everyone, everywhere.**

Using innovative funding strategies to incentivise collaborative research

- Awarding prize money for promising new TB drugs at an early stage
- facilitating the early sharing of clinical data and intellectual property so that promising candidates can easily be combined
- Offering grant-based funding to pay for clinical trials in new treatment regimens

For more information:


<http://www.msfaaccess.org/spotlight-on/3p-project-new-approach-developing-better-treatments-tb>

Benefits of 3P over current model

This framework offers **four benefits** over the current system:

- 1) **reduces the duplication** of research efforts thereby saving time and money
- 2) “**de-risks**” potential combinations as early and as affordably as possible
- 3) **accelerates** drug combination development
- 4) **reduces the risk** of resistance to new compounds

Organisational Chart



Thanks!

